Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
February 15th 2017

From Bench to Community Oncology Clinic: The Promise of Immunotherapy

Sumeet Chandra, MD
Community oncologists will be at the forefront of using immunotherapies and will need to be strong advocates for greater information and affordability of therapies.
Site Logo
February 15th 2017

Managing Patient Expectations With Immuno-Oncology

Surabhi Dangi-Garimella, PhD
Immunotherapy treatments are not without side effects. What do patients and their families need to know so they are more aware?
Dr Karen van Caulil Says Employers Will See Value of OCM
February 15th 2017

Dr Karen van Caulil Says Employers Will See Value of OCM

Employers are generally not very familiar with the Oncology Care Model (OCM) yet, but support will grow as they see that the key goals of the OCM overlap with their own concerns, predicted Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.
Site Logo
February 14th 2017

CAR-T Cells: The Next Era in Immuno-Oncology

Bruce A. Feinberg, DO Jennifer Fillman, MBA Justin Simoncini, MBA, MPH Chadi Nabhan, MD, MBA, FACP
An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Site Logo
February 14th 2017

Sustained Response to Immune Checkpoint Inhibitors Could Influence Standard of Care

Surabhi Dangi-Garimella, PhD
A new study to be presented at the 2017 Genitourinary Cancers Symposium has found that some patients with advanced renal cell carcinoma had a durable response after treatment discontinuation.
Site Logo
February 14th 2017

Patient Navigation in Immuno-Oncology

Shawn M. Regis, PhD
Patient navigation is immensely helpful in relieving some of the burden placed on cancer patients, and there are some particularly unique aspects of navigation as it pertains to immuno-oncology.
Site Logo
February 13th 2017

AJMCtv® Interviews, February 2017

Nicole Beagin Laura Joszt, MA
AJMCtv® interviews let you catch up with experts in healthcare. Topics include challenges with immuno-oncology, including the patient voice in treatment decisions, and why payers should cover genomic testing.
Site Logo
February 13th 2017

Navigator Program Lowered Costs, Utilization for Elderly Cancer Patients

Christina Mattina
A program linking elderly cancer patients to lay navigators was shown to substantially reduce costs and decrease hospitalizations, making it an appealing tool for providing value-based oncology care.
Site Logo
February 13th 2017

Predicting Response to SCT in Patients With MDS

Surabhi Dangi-Garimella, PhD
A new study has identified key mutations that can direct the conditioning regimen prior to an allogenic hematopoietic stem cell transplant (SCT) in patients with myelodysplastic syndrome (MDS), leading to a better response.
Debra Madden Discusses Importance of Educating Patients on Immuno-Oncology Risks
February 13th 2017

Debra Madden Discusses Importance of Educating Patients on Immuno-Oncology Risks

Immuno-oncology is often portrayed as having less severe side effects than chemotherapy, but patients need to be aware that it does carry some risks, said Debra L. Madden, cancer research advocate and patient representative. Patients should not hesitate to report any adverse effects to their doctor.
Site Logo
February 12th 2017

MD Anderson Now an Oncology "Superhub" for Project ECHO

Surabhi Dangi-Garimella, PhD
MD Anderson Cancer Center, which first established its oncology-focused ECHO program in 2014 has now adopted a much bigger role, of a “superhub.”
Podcast: This Week in Managed Care - Drop in ACA Enrollment, and Other News
February 11th 2017

Podcast: This Week in Managed Care - Drop in ACA Enrollment, and Other News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: February 10, 2017
February 10th 2017

This Week in Managed Care: February 10, 2017

This week, the top managed care stories included final enrollment numbers for the Affordable Care Act for 2017, a report that revealed low rates of lung cancer screening, and a study found that a population-based weight management strategies can prevent diabetes.
Site Logo
February 10th 2017

The Complex Relation Between Clinical Outcomes, Drug Approval, and Drug Price

Surabhi Dangi-Garimella, PhD
Does an FDA approval guarantee clinical benefit of a drug? How does it influence drug price?
Site Logo
February 9th 2017

Hopkins' Researchers Discover Carcinogenic Metals in E-Cigarette Liquid

Surabhi Dangi-Garimella, PhD
Analysis of the liquid used to make the aerosol in e-cigarettes has led to the discovery of high levels of 5 potentially toxic heavy metals.
Site Logo
February 8th 2017

Michigan Study Finds Obesity Lowers Hospice Use Among Seniors

Surabhi Dangi-Garimella, PhD
A long-term health study has found that seniors with a higher body mass index were less likely to make use of hospice care. Additionally, obese seniors spent significantly fewer days in hospice care than their nonobese counterparts.
Site Logo
February 8th 2017

Breast Cancer Patients Not Getting Desired Genetic Testing, Counseling

Christina Mattina
A recent JAMA study found that women with breast cancer would generally like to receive genetic testing and counseling, but less than one-third actually receive it.
Site Logo
February 7th 2017

PMC Report Proposes Strategies for Clinical Integration of Personalized Medicine

Surabhi Dangi-Garimella, PhD
The Health Care Working Group of the Personalized Medicine Coalition (PMC) has published a new report that provides a framework for the successful integration of personalized medicine in the clinic.
Site Logo
February 7th 2017

Low-Income Women Less Likely to Keep Jobs After Breast Cancer Treatment

Christina Mattina
Women with breast cancer are twice as likely to return to work after treatment if their employer makes accommodations for them, but workplace accommodation and job retention are significantly lower for low-income and minority women.
Site Logo
February 6th 2017

ACS Study Voices Concerns Over Low US Lung Cancer Screening Rates

Surabhi Dangi-Garimella, PhD
Lung cancer screening rates in the United States remained low and unchanged in 2015 despite recommendations that high-risk current and former smokers be screened.
David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials
February 6th 2017

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

The FDA has been willing to explore the utilization of surrogate endpoints like tumor response in clinical trials, but it is unclear whether these endpoints correlate with overall survival, said David Fabrizio of Foundation Medicine, Inc. However, he emphasized that overall survival does not necessarily benefit the patient if the additional days gained are not quality days.
Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data
February 6th 2017

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

Cancer Outcomes Tracking and Analytics (COTA) focuses on stratifying cancer patients by their many subtypes to understand the different treatments, outcomes, and costs for each, according to Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Site Logo
February 2nd 2017

Report Commissioned by COA Explores "Murky" World of Pharmacy DIR Fees

Christina Mattina
A white paper commissioned by the Community Oncology Alliance (COA) delved into the practice of “direct and indirect remuneration” fees administered by pharmacy benefit managers and how they could drive up drug prices for Medicare Part D beneficiaries and taxpayers.
Site Logo
February 1st 2017

Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US

AJMC Staff
Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.
Site Logo
February 1st 2017

A Focus on Lifestyle and Appropriate Screening During National Cancer Prevention Month

Surabhi Dangi-Garimella, PhD
During the National Cancer Prevention Month, there will be renewed fervor among healthcare providers to ensure individuals pay greater attention toward preventive measures against cancer.
Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria
February 1st 2017

Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria

The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.
Site Logo
January 31st 2017

Study Recommends Measures to Fill Quality Gaps in Oncology Care

Surabhi Dangi-Garimella, PhD
A multicollaborative study has identified gaps in existing quality measures used by accountable care programs that could result in missed opportunities to improve patient outcomes.
Kim Eason on the Benefits of Patient-Centered Medical Homes
January 31st 2017

Kim Eason on the Benefits of Patient-Centered Medical Homes

Patient-centered medical homes are valuable because they allow insurers to look at the cost of all of the patient’s treatments, services, and physicians throughout the continuum of care, explained Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.
Site Logo
January 30th 2017

Leaders of Cardiologists, Oncologists Decry Travel Ban

Mary Caffrey
The American College of Cardiology is set to hold its annual meeting in the nation's capital March 17-20, 2017.
Site Logo
January 30th 2017

Need for Switch to Incretins in T2D an Indicator of Pancreatic Cancer

Surabhi Dangi-Garimella, PhD
A retrospective analysis of evidence from prescription data gathered in Belgium and Italy has found that uncontrolled diabetes might be an early sign of pancreatic cancer.
<1
...
828384858687888990
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo